Table 1 Baseline patient characteristics, n = 233
Characteristic | Number | % | Median (range) | |
|---|---|---|---|---|
Gender | Male | 124 | 53 | |
Age | Median (range) | 57 (21-88) | ||
Performance status | ECOG 0 | 105 | 45 | |
ECOG 1 | 122 | 52 | ||
ECOG 2 | 6 | 3 | ||
No. of prior treatments | 2 (0-14) | |||
0-2 | 135 | 58 | ||
≥ 3 | 98 | 42 | ||
Primary tumor site | Gastrointestinal | 108 | 46 | |
Thoracic, Head & Neck | 58 | 25 | ||
Breast & Gynecological | 40 | 17 | ||
Urologic: Sarcoma: Other | 9: 5: 13 | 4:2:6 | ||
Type of trial | Targeted agent alone | 89 | 38.2 | |
Cytotoxic agent alone | 8 | 3.4 | ||
Combined | 136 | 58.4 | ||
No. of metastatic sites | 3 (1-4) | |||
Locoregional disease* | 20 | 9 | ||
1-2 sites | 138 | 59 | ||
> 2 sites | 75 | 32 | ||
Site of metastasis | Liver | 121 | 52 | |
Lung | 129 | 55 | ||
Bone | 39 | 17 | ||
Baseline albumin | 41 g/L (28-48 g/L) | |||
< 35 g/L | 8 | 3 | ||
≥ 35 g/L | 225 | 97 | ||
Baseline LDH | 224 U/L (93-3132 U/L) | |||
Normal LDH | 142 | 61 | ||
Elevated LDH > ULN | 91 | 39 | ||
Baseline hemoglobin | 12.5 g/dL (8.2-17.1 g/dL) | |||
< 12 g/dL | 90 | 39 | ||
≥ 12 g/dL | 143 | 61 | ||
Baseline WBC | 7 × 109/L (2.3-20.7 × 109/L) | |||
≤ 10.5 × 109/L | 203 | 87 | ||
> 10.5 × 109/L | 30 | 13 | ||
Baseline platelets | 264 × 109/L (106-832 × 109/L) | |||
≤ 400 × 109/L | 204 | 88 | ||
> 400 × 109/L | 29 | 12 |